Vascular Medicine

Novel markers of peripheral arterial disease

Farhan J Khawaja and Iftikhar J Kullo

Published by:

$SAGE

http://www.sagepublications.com

On behalf of:

Society for
Vascular Medicine

Society for Vascular Medicine

Additional services and information for *Vascular Medicine* can be found at:

Email Alerts: http://vmj.sagepub.com/cgi/alerts

Subscriptions: http://vmj.sagepub.com/subscriptions

Reprints: http://www.sagepub.com/journalsReprints.nav

Permissions: http://www.sagepub.com/journalsPermissions.nav

Citations: http://vmj.sagepub.com/content/14/4/381.refs.html

Novel markers of peripheral arterial disease

Farhan J Khawaja Department of Medicine, Division of Cardiovascular Diseases and the Gonda Vascular Center, Mayo Clinic College of Medicine and **Iftikhar J Kullo** Department of Medicine, Division of Cardiovascular Diseases and the Gonda Vascular Center, Mayo Clinic College of Medicine

Abstract: Peripheral arterial disease (PAD), a relatively common manifestation of atherosclerotic vascular disease, is associated with significant morbidity and mortality. Although conventional risk factors contribute to the onset and progression of PAD, the role of 'novel' biomarkers in pathways of inflammation, thrombosis, lipoprotein metabolism, and oxidative stress in determining susceptibility to PAD is being increasingly recognized. Validation of novel risk factors for PAD may allow earlier detection, an improved understanding of disease etiology and progression, and the development of new therapies. In this review, we discuss available evidence for associations between novel circulating markers and several aspects of PAD including disease susceptibility, progression, functional limitation, and adverse outcomes.

Keywords: inflammation, peripheral arterial disease, risk factors

Introduction

Atherosclerotic vascular disease affects large- and medium-sized arteries of most circulatory beds and is the leading cause of death and disability in developed countries. Lower-extremity atherosclerotic peripheral arterial disease (PAD) is a significant public health problem in the USA, with an estimated 8–10 million affected individuals.[1] Although conventional risk factors are known to contribute to the development of PAD, the role of 'novel' biomarkers in pathways of inflammation, thrombosis, lipoprotein metabolism, and oxidative stress in determining susceptibility to PAD is not fully defined. Validation of novel risk markers for PAD may allow earlier detection, an improved understanding of disease etiology and progression, and the development of new therapies.

Since PAD may have varying clinical presentations, a valuable tool for investigating novel markers for this disease is the ankle–brachial index (ABI), an objective, reproducible, non-invasive measure that correlates with PAD severity.[2] An ABI ≤ 0.90 is 95% sensitive and 90% specific for the presence of a ≥ 50% narrowing of a lower extremity artery and is used in the clinical setting to establish a diagnosis of PAD.[3] The change in ABI over time provides a measure of PAD progression and ABI also provides prognostic information; patients with severe PAD (ABI ≤ 0.40) have a significantly decreased survival, with only 24% of patients alive at 12 years.[4] However, ABI is not strongly correlated with functional capacity in patients with PAD.[5–7]

In recent years, several 'novel' circulating markers, including C-reactive protein (CRP), fibrinogen, lipoprotein(a) (Lp(a)), and homocysteine, have been examined as potential risk factors for atherothrombotic vascular disease. This review will focus on the association of these and additional markers with PAD, including markers of inflammation, thrombosis, lipoprotein metabolism, and oxidative stress (Table 1). Where data are available, we discuss these markers not only as predictors of onset of PAD, but also progression, functional capacity, and adverse outcomes in PAD patients.

Inflammation

A substantial body of evidence has accumulated to support a key role for inflammation in the development and progression of atherosclerosis. Several studies have investigated the association of various markers of vascular inflammation including acute phase reactants (CRP), cytokines (interleukin-6 (IL-6)), cellular adhesion molecules (CAMs), white blood cell (WBC) count, and beta2-microglobulin, with manifestations of atherosclerotic vascular disease.

Corresponding author: Iftikhar J Kullo, Division of Cardiovascular Diseases, Gonda Vascular Center, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA. E-mail: kullo.iftikhar@mayo.edu

Table 1 Novel circulating markers that have been implicated in PAD

Inflammatory markers
  C-reactive protein
  Interleukin-6
  Cellular adhesion molecules
  White blood cell count
  Beta2-microglobulin
  Monocyte chemoattractant protein-1
  Soluble CD40 ligand
  Myeloperoxidase
  Neopterin
  Osteoprotegerin
  Tumor necrosis factor-alpha
Thrombotic markers
  Fibrinogen
  D-dimer
  von Willebrand factor
  Tissue plasminogen activator
  Plasminogen activator inhibitor
Lipoprotein metabolism
  Lipoprotein-associated phospholipase A2
  Lipoprotein(a)
Oxidative stress markers
  Glutathione peroxidase 1 activity
  8-iso-prostaglandin F2α
  Vitamin C (L-ascorbic acid)
Matrix remodeling
  Matrix metalloproteinases and their inhibitors
  Pregnancy-associated plasma phosphatase
Angiogenesis
  Vascular endothelial growth factor
  Flt-1
  Angiopoietin
  Tie-1
Other markers
  Homocysteine
  Asymmetric dimethylarginine

C-reactive protein (CRP)

CRP is an acute phase reactant and plasma levels increase in response to inflammatory processes. It is a pentameric protein primarily produced in the liver in response to IL-6 and other inflammatory cytokines.[8] Recent data suggest that CRP is also synthesized in the smooth muscle cells of atherosclerotic plaques.[9] Initially thought to simply be a marker of systemic inflammation, CRP may be mechanistically involved in atherosclerotic plaque development and instability. Putative mechanisms of vascular damage due to CRP include downregulation of endothelial nitric oxide synthase, increased endothelial expression of cell adhesion molecules (CAMs), activation of the complement system, upregulation of low-density lipoprotein (LDL) phagocytosis by macrophages, and vascular smooth muscle cell migration, proliferation, and neo-intimal formation.[10–17]

Not only has CRP been shown to be an independent predictor of myocardial infarction and stroke in asymptomatic individuals,[18,19] it was also predic-

tive of onset of symptomatic PAD in a cohort of 14,916 mostly white men (ages 40–84 years) followed for a mean of 9 years[20,21] and in a prospective observational study of 27,935 women aged ≥ 45 years followed for a mean of 12 years.[22] Several studies also investigated the relationship between the ABI and CRP. A higher CRP level was associated with a lower ABI in several studies, although the relationship was attenuated after adjustment for conventional risk factors and physical activity.[23–30] In the National Health and Nutrition Examination Survey (NHANES), CRP was not significantly associated with PAD (ABI ≤ 0.9) after adjustment for measures of insulin resistance;[31] and in the Edinburgh Artery Study,[32] CRP was not significantly associated with PAD after adjustment for plasma levels of IL-6. Further, among symptomatic PAD patients, CRP levels were not found to be significantly different in varying grades of claudication severity, implying that CRP may not be related to the severity of obstructive PAD.[33] Given that both elevated CRP as well as a low ABI have been associated with increased risk of cardiovascular events [34,35] and the two do not appear to be strongly correlated, and may predict risk through independent pathways, measurement of both may provide incremental information. CRP levels may be a marker of plaque instability and vascular inflammation that leads to disease progression and adverse cardiovascular outcomes, whereas ABI is a marker of atherosclerotic burden.

CRP has also been studied in PAD patients as a marker of disease progression, functional activity, and adverse cardiovascular events such as myocardial infarction and stroke. Plasma levels of CRP predicted progression of PAD (as determined by a decrease in ABI over time) in two large population-based longitudinal cohort studies: the Rotterdam Study (*n* = 7987, mostly white men and women in The Netherlands; age ≥ 55; follow-up 6.5 years)[36] and the Edinburgh Artery Study (*n* = 1592, mostly white men and women in the UK; ages 55–74; follow-up 5–12 years),[32] as well as two smaller studies, over a period of 3–12 years.[37,38] Inflammation also appears to be associated with a decline in function and physical activity often seen in patients with PAD and resulting in a significant impact on quality of life. Higher levels of CRP were correlated with impaired functional capacity, decreased physical activity, and future functional decline in several cohort studies.[39–43]

CRP is predictive of adverse cardiovascular events in PAD patients,[33,44] including those undergoing revascularization.[33] An elevated CRP was also predictive of all-cause and cardiovascular mortality at 1 year but not at 2–3 years in a prospective cohort study of 377 patients with PAD.[45] These data suggest that inflammation may be related to

plaque instability in patients with PAD. In a prospective study of 110 patients referred to a non-invasive vascular laboratory, CRP provided prognostic information in addition to ABI.[46] A high CRP (> 3.0 mg/l) and a low ABI (ABI < 0.9) were associated with an odds ratio of 2.6 and 4.0, respectively, for adverse cardiovascular events (myocardial infarction, stroke, coronary or lower extremity revascularization, or death); when both were present, the odds ratio increased to nearly 6. Combined use of a marker of inflammation and ABI may therefore have a greater predictive value for cardiovascular events than either measure alone.

CRP may be predictive of the risk of developing symptomatic PAD independent of conventional risk factors, but further studies are needed to confirm its clinical utility in this regard. Perhaps of greater clinical relevance is the fact that circulating CRP levels appear to be predictive of cardiovascular events and mortality in patients with known PAD and may also be associated with disease progression and functional decline. Whether lowering of plasma CRP levels will benefit patients with PAD is not known. Several interventions have been shown to reduce CRP levels including diet,[47] moderate alcohol consumption,[48] statins,[49,50] fibrates,[51] and fish oil.[52] A small molecule that inhibits CRP-related complement activation has been synthesized and was shown to reduce the size of myocardial infarction in rats.[8] Prospective randomized controlled trials are needed to investigate whether lowering CRP levels reduces disease progression, mortality, or functional decline in PAD.

Interleukin-6 (IL-6)

IL-6 is an inflammatory cytokine produced by hepatocytes, lymphocytes, and endothelial cells.[53] Whether IL-6 is associated with incident PAD, PAD severity, or cardiovascular events in PAD patients is not known. However, in the Edinburgh Artery Study, IL-6 was the strongest predictor of PAD progression over a 12-year period, and was the only biomarker to remain independently associated with disease progression after all 'novel' biomarkers and conventional risk factors were included in the analysis.[32] IL-6 is the stimulus for CRP production in the liver, and it is more proximal in the inflammatory cascade. However, it is less abundant in the plasma and the assays are not as robust, diminishing its potential for clinical use. The findings of several studies suggest that IL-6 levels may be regulated by the level of physical activity. Although IL-6 levels are significantly increased after exercise in PAD patients,[54] a higher IL-6 level has been associated with lower functional capacity in such patients.[55]

Cellular adhesion molecules

Cellular adhesion molecules (CAMs), expressed on the vascular endothelium and circulating leukocytes, mediate recruitment of leukocytes to the vascular wall and into sub-endothelial spaces and are implicated in atherogenesis.[56] Brevetti et al.[56] have summarized the evidence for CAMs as markers for the presence, severity, extent of PAD, and the risk of adverse cardiovascular events. In the Physicians' Health Study, soluble intercellular adhesion molecule-1 (sICAM-1) was associated with an increased risk of developing symptomatic PAD in men,[57] and similar findings were reported in the Women's Health Study.[22] In the Edinburgh Artery Study, sICAM-1 predicted PAD progression over a 12-year period.[32] Khaleghi et al. reported that sICAM-1 and soluble vascular cell adhesion molecule-1 (sVCAM-1) were associated with the presence of PAD in African Americans, but not in non-Hispanic whites.[58] There are no therapies that specifically lower CAMs although statins have been shown to decrease plasma CAM levels.[59] Succinobucol, a potent antioxidant that may inhibit CAMs, did not reduce adverse cardiovascular events (death, cardiac arrest, MI, stroke, unstable angina, or coronary revascularization) after myocardial infarction.[60] Clinical trials of this novel agent and other interventions that reduce CAM levels have yet to be performed in PAD patients.

WBC count

In the NHANES (1999–2002), a significant cross-sectional association of inflammatory markers (WBC count, fibrinogen and CRP level) with the presence of PAD (ABI < 0.9) was noted.[61] A WBC count in the top quartile (> $7.3 \times 10^3/\text{mm}^3$) was associated with an odds ratio of 1.67 for PAD compared to the bottom quartile (≤ $4.9 \times 10^3/\text{mm}^3$). A subsequent analysis of the NHANES database found that monocytes were the only WBC subtype significantly and independently associated with PAD.[62] Grau et al.[63] in a study of more than 18,000 patients with known atherosclerotic vascular disease (history of stroke, myocardial infarction, or symptomatic PAD) found that WBC count > $8.2 \times 10^3/\text{mm}^3$ (top quartile) was associated with a higher risk of vascular death (RR = 1.51) when compared with the WBC count ≤ $5.85 \times 10^3/\text{mm}^3$ (bottom quartile). The association of WBC count with all-cause mortality was not reported. Haumer et al.[64] followed 398 patients with symptomatic PAD (requiring revascularization or salvage for critical limb ischemia) for a median of 20 months. Compared to patients with a neutrophil count < 4.4 ($\times 10^3/\text{mm}^3$) (bottom tertile), those with a neutrophil count > 5.8 ($\times 10^3/\text{mm}^3$) (highest tertile) were at a

higher risk of major adverse cardiovascular events (myocardial infarction, need of percutaneous intervention, coronary bypass, stroke, carotid revascularization) (HR = 1.8) and death (HR = 3.4) and composite of myocardial infarction, stroke and death (HR = 2.2).

Although the WBC count could simply be a marker of inflammation in the setting of atherosclerotic vascular disease, it is possible that WBC may have a pathogenic role by activating various cascades, favoring plaque progression and rupture leading to acute coronary (or other ischemic) syndromes.[65,66] The possible mechanisms by which an elevated WBC count may be related to adverse outcomes have been reviewed by Madjid et al.[67] and Coller[66] and include increased inflammation, endothelial damage, procoagulant effects and microvascular damage. Indeed, Coller has proposed a clinical trial using agents that reduce the WBC count, such as hydroxyurea, in patients with atherosclerotic vascular disease and increased risk of death.[66]

Beta2-microglobulin

Beta2-microglobulin is a component of the major histocompatibility complex class I molecule. Wilson et al.[68] performed comparative proteomic profiling of PAD patients and controls and found that serum levels of beta2-microglobulin were higher in PAD than in non-PAD patients. This finding was validated by the investigators in 237 subjects referred for coronary angiography who were also screened for PAD. Plasma beta2-microglobulin levels were higher in PAD patients than in non-PAD patients with coronary artery disease and beta2-microglobulin levels were independently associated with ABI.[68] Further studies are needed to determine the clinical utility of this biomarker.

Other inflammatory markers

The association between PAD and several other inflammatory markers has been examined in a limited number of studies. In the Atherosclerotic Risk in Communities (ARIC) study, monocyte chemoattractant protein-1 (MCP-1) was associated with an ABI ≤ 0.90.[69] MCP-1[55] and soluble CD40L[55,70] were associated with the angiographic severity of PAD. Myeloperoxidase (MPO) was associated with adverse cardiovascular events in a cohort of 156 patients with PAD,[71] and with an ABI ≤ 0.90 in a bi-ethnic cohort of mostly hypertensive adults.[72] Serum osteoprotegerin was also associated with an ABI ≤ 0.90 in the latter cohort.[73] Circulating neopterin[74] and tumor necrosis factor alpha (TNF-α) levels[74] were found to be associated with 1-year mortality in patients with PAD.

Thrombosis

Thrombosis serves an important biologic function to reduce intravascular blood loss through the activation of the clotting cascade, which leads to fibrin and platelet deposition at the site of vascular injury. This cascade has been implicated in the formation and progression of atherosclerotic plaque as well as in the propensity towards acute cardiovascular events. Several markers of thrombosis including fibrinogen and D-dimer have been studied to characterize the relationship between thrombosis and PAD, whereas the association between PAD other thrombotic markers including von Willebrand factor (vWF), tissue plasminogen activator (tPA), and plasminogen activator inhibitor (PAI-1) is less well established.

Fibrinogen

Fibrinogen – a glycoprotein synthesized in the liver – is a key component of thrombus formation, a known acute phase reactant, and also a major determinant of plasma viscosity. Fibrin, the cleaved product of fibrinogen, plays an essential role in platelet adhesion and aggregation in clot formation. Fibrinogen levels are in part genetically determined,[75] and are also increased with age, obesity, diabetes, menopause,[76] and smoking.[77] A number of prospective cohort studies have shown plasma fibrinogen levels to be an independent predictor of future onset of PAD.[21,78,79] Plasma fibrinogen was predictive of the development of claudication in the Framingham Heart Study and is included in the Framingham equation to assess the risk of PAD.[80]

Higher fibrinogen levels have also been independently associated with a lower ABI in most[24,81–85] but not all[29] cross-sectional cohort studies. A higher plasma fibrinogen level was associated with a lower ABI in both African Americans and non-Hispanic whites belonging to sibships ascertained on the basis of hypertension.[27,86] In the Edinburgh Artery Study, plasma fibrinogen and a history of smoking had a synergistic effect in reducing ABI.[87] In the same study, the fibrinogen level was predictive of progression of PAD over 12 years, although this association was attenuated after adjustment for markers of inflammation including CRP and IL-6.[88] In contrast to CRP, fibrinogen has not been independently associated with physical activity levels or other measures of lower extremity functioning in patients with PAD.[39–42] However, fibrinogen levels are independently predictive of cardiovascular mortality in PAD patients.[89]

Fibrinogen levels are reduced by smoking cessation, exercise, and alcohol.[90] Among drugs, estrogens lower fibrinogen levels in contrast to their effects on raising CRP levels.[91] Fibrates have significant fibrinogen-lowering effects,[92] but because they

concomitantly modify plasma lipids, these drugs are not ideal for trials to determine the specific effects of fibrinogen lowering. In a randomized controlled trial of bezafibrate in men with PAD, concomitant lowering of fibrinogen and triglyceride levels led to a significant reduction in non-fatal myocardial infarction, although there was no reduction in fatal myocardial infarction or stroke.[93]

D-dimer

The relationship between D-dimer, a product of fibrin degradation by plasmin, and PAD is controversial. An elevated D-dimer has been associated with a lower ABI in several cross-sectional studies.[24,29,94] In the Edinburgh Artery Study, D-dimer was not independently associated with PAD progression after adjustment for CRP and IL-6 levels.[88] However, participants with the highest D-dimer and IL-6 levels had the greatest decline in ABI over a 12-year period.[88] McDermott et al. have demonstrated an elevated D-dimer to be associated with walking impairment,[41] functional capacity,[39] physical activity levels,[40] and functional decline over time.[42] Whether D-dimer is involved in the pathophysiology of functional impairment in PAD patients or is simply a marker of the same is not established.[38] In a study of 384 subjects designed to examine the effect of risk factors on PAD progression, D-dimer was associated with an increased risk of myocardial infarction, but not with PAD progression. In another prospective study of 377 men and women with PAD, D-dimer was associated with all-cause mortality during the first year of follow-up but not 2–3 years after biomarker measurement, suggesting that this biomarker may be a better predictor of short-term rather than long-term outcomes.[45]

Other thrombotic markers

Higher levels of vWF were associated with a lower ABI in a cross-sectional analysis of the ARIC study [95] but not with the development of PAD in the Edinburgh Artery Study[96] or the ARIC study.[79] Neither tPA or plasminogen activator inhibitor-1 (PAI-1) were associated with ABI in the ARIC study[95] and in another cross-sectional study.[29] In the Edinburgh Artery Study, tPA was only weakly associated with the development of PAD. The prognostic value of PAI-1 in the setting of PAD is not known. These two markers were also not associated with physical activity levels in PAD patients.[40]

Lipoprotein markers

LDL cholesterol is an established risk factor for atherosclerotic vascular disease and a major therapeu-

tic goal in PAD patients is the reduction of LDL cholesterol levels. New evidence suggests that several novel lipoprotein markers may also be associated with the development and progression of atherosclerotic vascular disease including PAD.

Lipoprotein-associated phospholipase A2 (Lp-PLA$_2$)

Lp-PLA$_2$ is a novel marker of increased risk of coronary heart disease (CHD) and stroke.[97] Whether Lp-PLA$_2$ is associated with future risk of PAD is not known. In a study of 1820 community-based subjects based in Rotterdam, Lp-PLA$_2$ was associated with an ABI < 0.90; however, the association was no longer present after adjustment for total and high-density lipoprotein (HDL) cholesterol.[98] In a prospectively followed cohort of PAD patients, Lp-PLA$_2$ was not associated with adverse cardiovascular events.[99] The available data suggest that Lp-PLA$_2$ is not associated with PAD or cardiovascular mortality in PAD patients.

Lipoprotein(a) (Lp(a))

Lp(a) is a circulating lipoprotein that resembles LDL in that both molecules have apo B-100 as the surface apolipoprotein. In addition, Lp(a) has a unique glycoprotein, apo(a), bound to apo B-100 by a disulfide bond; apo(a) resembles plasminogen and competitively binds to plasminogen receptor sites.[100] Several mechanisms have been proposed for the atherogenic effects of Lp(a), including inhibition of plasminogen activity related to the structural homology of apo(a) to plasminogen,[100] induction of PAI-1, inhibiting release of tPA,[101,102] and vascular smooth muscle cell proliferation.[103]

Studies investigating the association between Lp(a) levels and PAD have yielded conflicting results. The Physicians' Health Study[21] did not find Lp(a) levels to be predictive of symptomatic PAD. However, several cross-sectional, case–control studies have found an association between elevated Lp(a) levels and PAD in various populations including those with premature PAD (men aged < 45),[104,105] those with known PAD,[106,107] and those referred for lower extremity revascularization.[108] Other cross-sectional cohort studies have found significant associations between Lp(a) levels and PAD (ABI < 0.90) in the elderly ($n = 369$),[109] and in type II diabetics ($n = 557$).[110] Additionally, a prospective longitudinal observational study found Lp(a) to be an independent predictor of progression of PAD (as determined by a decrease in ABI over 4.6 ± 2.5 years).[37]

Plasma levels of Lp(a) largely depend on the size of the apo(a) isoform present, and are inversely related to the number of apo(a) kringle IV repeats.[111] Elevated Lp(a) levels may be more atherogenic in the presence of small apo(a) size (defined as < 22 kringle 4 (K4) repeats) versus larger apo(a)

isoforms.[112] In African Americans, high Lp(a) levels are less likely to be associated with the presence of small apo(a) isoforms than in Caucasians.[113] This observation may explain why elevated Lp(a) levels have not been consistently associated with increased cardiovascular risk in African Americans.[114] In one study,[115] elevated levels of Lp(a) with small apo(a) isoforms were associated with the angiographic extent of coronary artery disease in both African American and Caucasian men. In a bi-ethnic cohort of mostly hypertensive individuals, higher Lp(a) levels were associated with PAD in African Americans but not non-Hispanic whites.[27]

Pharmacologic options for lowering elevated Lp(a) levels are limited. Statins do not appear to have a significant effect on Lp(a) levels.[116] However, lowering of LDL cholesterol levels may diminish the risk of adverse cardiovascular events due to elevated Lp(a).[117] Estrogens decrease plasma Lp(a) concentration,[118] and a post hoc analysis from the Women's Health Study revealed that estrogens had a favorable impact on cardiovascular events in the women who had elevated Lp(a) levels.[119] Niacin has been shown to have Lp(a)-lowering effects, alone[120] and in conjunction with neomycin[121] and statins.[122] No clinical trials have been performed to confirm whether a decrease in Lp(a) levels leads to improved cardiovascular outcomes, in part because drugs that specifically and significantly lower Lp(a) are not yet available.

Other markers

Homocysteine

Homocysteine is an amino acid intermediate produced during the metabolism of methionine.[123] Its role in atherogenesis was proposed subsequent to the observation that children and young adults with cystathione beta-synthase deficiency and markedly elevated homocysteine levels developed premature atherosclerosis. Homocysteine may promote atherosclerosis through several mechanisms, including increased oxidant stress and adverse effects on endothelial function.[123] Increased homocysteine levels may result from genetic polymorphisms in enzymes related to its metabolism, as well as aging, menopause, hypothyroidism, low B vitamin and folic acid levels, and chronic kidney disease.[124–128]

Several studies found homocysteine levels to be associated with PAD, the Physicians' Health Study being a notable exception.[21] In a cross-sectional population-based study, higher homocysteine levels were associated with a reduced ABI (<0.90).[129] Elevated homocysteine levels were also associated with a lower ABI in a multiethnic cohort of predominantly hypertensive adults,[27] with symptomatic

PAD in a referral population,[108] and with angiographic severity of PAD in type II diabetic patients.[130] A meta-analysis found elevated homocysteine levels (> 15 μmol) to be related to atherosclerotic disease in several vascular beds, but most strongly to PAD.[131] Additionally, elevated homocysteine levels predict all-cause and cardiovascular death in patients with PAD.[132,133] Of note, in an analysis of 4447 NHANES participants,[134] the association between PAD and plasma homocysteine was attenuated after adjustment for plasma levels of the heavy metals lead and cadmium, suggesting that homocysteine may be a marker of an as yet unknown atherogenic factor.

Vitamins B6, B12, and folic acid reduce homocysteine levels; however, the Heart Outcomes Prevention Evaluation (HOPE2) study found that B vitamins do not reduce the risk of major cardiovascular events (excluding stroke) in patients with vascular disease.[135] Another recent trial of women at high risk of developing cardiovascular disease demonstrated that lowering homocysteine with B vitamins and folic acid did not lower cardiovascular mortality.[136] The results of these trials indicate that treating homocysteine levels with B vitamins and folate in patients with known vascular disease is not currently warranted. However, the HOPE2 findings do not diminish the fact that homocysteine is a marker for increased cardiovascular risk, especially PAD. The role of homocysteine in PAD appears to be complex, and further studies are needed to better understand the relationship of homocysteine and atherothrombosis, and whether pharmacologic agents (other than folate) that reduce homocysteine levels can alter cardiovascular outcomes.

Asymmetric dimethylarginine (ADMA)

Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of endothelial nitric oxide synthase, the enzyme that produces nitric oxide, a vasodilator with anti-inflammatory and anti-thrombotic effects. Plasma ADMA levels were elevated in patients hospitalized with symptomatic PAD[137] and predictive of adverse cardiovascular events (myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft, stroke, carotid revascularization, and death) in such patients.[138] Infusion of L-arginine (the substrate for nitric oxide production) improved walking distances and flow-mediated dilation in a study of patients with PAD.[139] However, a recent randomized controlled trial found no evidence of benefit in patients with PAD.[140]

Oxidative stress

Oxidative damage to lipids and proteins is implicated in the development of atherosclerotic vascular

disease.[141] To date, the data pertaining to any possible association between PAD and other markers of oxidative stress are sparse. In small, case–control studies, plasma levels of glutathione peroxidase-1 activity,[142] 8-iso-prostaglandin F2α,[143] and vitamin C (L-ascorbic acid)[29] have been associated with PAD. This is clearly an area that requires further investigation.

Matrix remodeling

Matrix metalloproteinases (MMP) and their inhibitors are markers of extracellular matrix turnover and have been associated with PAD in two case–control studies. The first study included 36 patients with intermittent claudication, 43 with critical limb ischemia, and 42 controls.[144] The second study included 51 type II diabetics with PAD, 42 type II diabetics without PAD, and 23 controls.[145] Pregnancy-associated plasma phosphatase (PAPP-A) is a zinc-binding metalloproteinase that was associated with PAD in a case–control study of 433 PAD patients and 433 controls.[146]

Angiogenesis

Vascular endothelial growth factor (VEGF) was associated with PAD in two case–control studies; the first included 70 patients with PAD and 70 controls,[143] and the second study included 234 patients with an ABI ≤ 0.8 and 50 controls.[147] Levels of the VEGF receptor, soluble Flt-1, were associated with PAD in the first study,[143] but not in the second one.[147] Plasma angiopoietin2 was increased in both intermittent claudication and critical limb ischemia compared with controls ($n = 23$ for intermittent claudication, $n = 23$ for critical limb ischemia, $n = 23$ for healthy controls).[148] A receptor tyrosine kinase specifically expressed in developing vascular endothelial cells, tie-2, plays an important role in angiogenesis. Soluble tie-2 levels were increased in patients with critical limb ischemia compared with controls ($n = 46$ patients with PAD, $n = 23$ controls).[148]

Conclusion

Considerable evidence supports the association of novel circulating markers with several aspects of PAD including: (1) the risk of developing symptomatic or asymptomatic PAD; (2) progression of PAD; (3) functional impairment; and (4) adverse cardiovascular events and mortality. However, significant gaps in knowledge remain. Given the complexity of atherosclerotic vascular disease, a single marker is unlikely to yield significant predictive or prognostic information and a multimarker approach is more likely to be useful. It is clear from this review that there are robust data to support an association of inflammation and thrombosis with PAD; whereas the data regarding the association of novel markers of lipoprotein metabolism, oxidative stress, and angiogenesis are still evolving.

New circulating markers could provide incremental information about the risk of developing PAD and add prognostic information beyond what is possible with the measurement of the ABI, particularly in the prediction of cardiovascular events and mortality.[27,149] Such knowledge could also lead to a better understanding of disease pathways with significant diagnostic and therapeutic implications. Further work is needed to develop clinically useful markers of PAD including novel assay platforms and statistical methodology, targeted approaches using candidate protein in etiologic pathways of disease, as well as an agnostic approach using discovery proteomics.

Acknowledgements

References

1 Criqui MH. Peripheral arterial disease – epidemiological aspects. *Vasc Med* 2001; **6**(suppl): 3–7.

2 Muller-Buhl U, Wiesemann A, Oser B, Kirchberger I, Strecker EP. Correlation of hemodynamic and functional variables with the angiographic extent of peripheral arterial occlusive disease. *Vasc Med* 1999; **4**: 247–251.

3 Doobay AV, Anand SS. Sensitivity and specificity of the ankle-brachial index to predict future cardiovascular outcomes: a systematic review. *Arterioscler Thromb Vasc Biol* 2005; **25**: 1463–1469.

4 McKenna M, Wolfson S, Kuller L. The ratio of ankle and arm arterial pressure as an independent predictor of mortality. Atherosclerosis 1991; **87**: 119–128.

5 Hirsch AT, Haskal ZJ, Hertzer NR et al. ACC/AHA Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic). *Circulation* 2006; **113**: e463–e654.

6 Feinglass J, McCarthy WJ, Slavensky R, Manheim LM, Martin GJ. Effect of lower extremity blood pressure on physical functioning in patients who have intermittent claudication. The Chicago Claudication Outcomes Research Group. *J Vasc Surg* 1996; **24**: 503–511, discussion: 511–512.

7 McDermott MM, Mehta S, Liu K et al. Leg symptoms, the ankle-brachial index, and walking ability in patients with peripheral arterial disease. *J Gen Intern Med* 1999; **14**: 173–181.

8 Pepys MB, Hirschfield GM, Tennent GA et al. Targeting C-reactive protein for the treatment of cardiovascular disease. *Nature* 2006; **440**: 1217–1221.

9 Calabro P, Willerson JT, Yeh ET. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. *Circulation* 2003; **108**: 1930–1932.

10 Verma S, Wang CH, Li SH et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. *Circulation* 2002; **106**: 913–919.

11 Yasojima K, Schwab C, McGeer EG, McGeer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. *Am J Pathol* 2001; **158**: 1039–1051.

12 Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. *Circulation* 2000; **102**: 2165–2168.

13 Pasceri V, Chang J, Willerson JT, Yeh ET. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. *Circulation* 2001; **103**: 2531–2534. Erratum in: *Circulation* 2001; **104**: 1992.

14 Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. *Circulation* 2001; **103**: 1194–1197.

15 Szmitko PE, Wang CH, Weisel RD, de Almeida JR, Anderson TJ, Verma S. New markers of inflammation and endothelial cell activation: Part I. *Circulation* 2003; **108**: 1917–1923.

16 Wang CH, Li SH, Weisel RD et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. *Circulation* 2003; **107**: 1783–1790.

17 Torzewski J, Torzewski M, Bowyer DE et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. *Arterioscler Thromb Vasc Biol* 1998; **9**: 1386–1392.

18 Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. *N Engl J Med* 1997; **336**: 973–979.

19 Albert CM, Ma J, Rifai N, Stampfer MJ, Ridker PM. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. *Circulation* 2002; **105**: 2595–2599.

20 Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. *Circulation* 1998; **97**: 425–428.

21 Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. *JAMA* 2001; **285**: 2481–2485.

22 Pradhan AD, Shrivastava S, Cook NR, Rifai N, Creager MA, Ridker PM. Symptomatic peripheral arterial disease in women: nontraditional biomarkers of elevated risk. *Circulation* 2008; **117**: 823–831.

23 Bloemenkamp DG, van den Bosch MA, Mali WP et al. Novel risk factors for peripheral arterial disease in young women. *Am J Med* 2002; **113**: 462–467.

24 Unlu Y, Karapolat S, Karaca Y, Kiziltunc A. Comparison of levels of inflammatory markers and hemostatic factors in the patients with and without peripheral arterial disease. *Thromb Res* 2006; **117**: 357–364.

25 Yu HI, Sheu WH, Song YM, Liu HC, Lee WJ, Chen YT. C-reactive protein and risk factors for peripheral vascular disease in subjects with Type 2 diabetes mellitus. *Diabet Med* 2004; **21**: 336–341.

26 Langlois M, Duprez D, Delanghe J, De Buyzere M, Clement DL. Serum vitamin C concentration is low in peripheral arterial disease and is associated with inflammation and severity of atherosclerosis. *Circulation* 2001; **103**: 1863–1868.

27 Khawaja FJ, Bailey KR, Turner ST, Kardia SL, Mosley Jr TH, Kullo IJ. Association of novel risk factors with the ankle brachial index in African American and non-Hispanic white populations. *Mayo Clin Proc* 2007; **82**: 709–716.

28 Santos S, Rooke TW, McConnell JP, Kullo I. Relation of markers of inflammation (C-reactive protein, white blood cell count, and lipoprotein-associated phospholipase A2) to the ankle-brachial index. *Vasc Med* 2004; **9**: 171–176.

29 McDermott MM, Green D, Greenland P et al. Relation of levels of hemostatic factors and inflammatory markers to the ankle brachial index. *Am J Cardiol* 2003; **92**: 194–199.

30 McDermott MM, Guralnik JM, Corsi A et al. Patterns of inflammation associated with peripheral arterial disease: the InCHIANTI study. *Am Heart J* 2005; **150**: 276–281.

31 Pande RL, Perlstein TS, Beckman JA, Creager MA. Association of insulin resistance and inflammation with peripheral arterial disease: the National Health and Nutrition Examination Survey, 1999 to 2004. *Circulation* 2008; **118**: 33–41.

32 Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD, Fowkes FG. C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study. *Circulation* 2005; **112**: 976–983.

33 Rossi E, Biasucci LM, Citterio F et al. Risk of myocardial infarction and angina in patients with severe peripheral vascular disease: predictive role of C-reactive protein. *Circulation* 2002; **105**: 800–803.

34 Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. *JAMA* 1998; **279**: 1477–1482.

35 Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. *Circulation* 2001; **103**: 1813–1818.

36 Van der Meer IM, de Maat MPM, Hak AE et al. C-reactive protein predicts progression of atherosclerosis measured at various sites in the arterial tree: The Rotterdam Study. *Stroke* 2002; **33**: 2750–2755.

37 Aboyans V, Criqui MH, Denenberg JO, Knoke JD, Ridker PM, Fronek A. Risk factors for progression of peripheral arterial disease in large and small vessels. *Circulation* 2006; **113**: 2623–2629.

38 Musicant SE, Taylor Jr LM, Peters D et al. Prospective evaluation of the relationship between C-reactive protein, D-dimer and progression of peripheral arterial disease. *J Vasc Surg* 2006; **43**: 772–780.

39 McDermott MM, Greenland P, Green D et al. D-dimer, inflammatory markers, and lower extremity functioning in patients with and without peripheral arterial disease. *Circulation* 2003; **107**: 3191–3198.

40 McDermott MM, Greenland P, Guralnik JM et al. Inflammatory markers, D-dimer, pro-thrombotic factors, and physical activity levels in patients with peripheral arterial disease. *Vasc Med* 2004; **9**: 107–115.

41 McDermott MM, Guralnik JM, Greenland P et al. Inflammatory and thrombotic blood markers and walking-related disability in men and women with and without peripheral arterial disease. *J Am Geriatr Soc* 2004; **52**: 1888–1894.

42 McDermott MM, Ferrucci L, Liu K et al. D-dimer and inflammatory markers as predictors of functional decline in men and women with and without peripheral arterial disease. *J Am Geriatr Soc* 2005; **53**: 1688–1696.

43 McDermott MM, Liu K, Guralnik JM et al. Functional decline in patients with and without peripheral arterial disease: predictive value of annual changes in levels of C-reactive protein and D-dimer. *J Gerontol A Biol Sci Med Sci* 2006; **61**: 374–379.

44 Vainas T, Stassen FR, de Graaf R et al. C-reactive protein in peripheral arterial disease: relation to severity of the disease and to future cardiovascular events. *J Vasc Surg* 2005; **42**: 243–251.

45 Vidula H, Tian L, Liu K et al. Biomarkers of inflammation and thrombosis as predictors of near-term mortality in patients with peripheral arterial disease: a cohort study. *Ann Intern Med* 2008; **148**: 85–93.

46 Beckman JA, Preis O, Ridker PM, Gerhard-Herman M. Comparison of usefulness of inflammatory markers in patients with versus without peripheral arterial disease in predicting adverse cardiovascular outcomes (myocardial infarction, stroke, and death). *Am J Cardiol* 2005; **96**: 1374–1378.

47 Jenkins DJ, Kendall CWC, Marchie A et al. Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. *JAMA* 2003; **290**: 502–510.

48 Sierksma A, van der Gaag MS, Kluft C, Hendriks HFJ. Moderate alcohol consumption reduces plasma C-reactive protein and fibrinogen levels; a randomized, diet-controlled intervention study. *Eur J Clin Nutr* 2002; **56**: 1130–1136.

49 Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. *Circulation* 2001; **103**: 1933–1935.

50 Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. *JAMA* 2001; **286**: 64–70.

51 Despres JP, Lemieux I, Pascot A et al. Gemfibrozil reduces plasma C-reactive protein levels in abdominally obese men with the atherogenic dyslipidemia of the metabolic syndrome. *Arterioscler Thromb Vasc Biol* 2003; **23**: 702–703.

52 Rallidis LS, Paschos G, Liakos GK, Velissaridou AH, Anastasiadis G, Zampelas A. Dietary alpha-linolenic acid decreases C-reactive protein, serum amyloid A and interleukin-6 in dyslipidaemic patients. *Atherosclerosis* 2003; **167**: 237–242.

53 Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. *Nat Clin Pract Rheumatol* 2006; **2**: 619–626.

54 Signorelli SS, Mazzarino MC, Di Pino L et al. High circulating levels of cytokines (IL-6 and TNFalpha), adhesion molecules (VCAM-1 and ICAM-1) and selectins in patients with peripheral arterial disease at rest and after a treadmill test. *Vasc Med* 2003; **8**: 15–19.

55 Nylaende M, Kroese A, Stranden E et al. Markers of vascular inflammation are associated with the extent of atherosclerosis assessed as angiographic score and treadmill walking distances in patients with peripheral arterial occlusive disease. *Vasc Med* 2006; **11**: 21–28.

56 Brevetti G, Schiano V, Chiariello M. Cellular adhesion molecules and peripheral arterial disease. *Vasc Med* 2006; **11**: 39–47.

57 Pradhan AD, Rifai N, Ridker PM. Soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, and the development of symptomatic peripheral arterial disease in men. *Circulation* 2002; **106**: 820–825.

58 Khaleghi M, Ali Z, Mosley Jr TH, Turner ST, Kullo IJ. Association of soluble cell adhesion molecules with ankle-brachial index in a biethnic cohort of predominantly hypertensive individuals. *Clin Chem* 2008; **54**: 1788–1795.

59 Van Haelst PL, van Doormaal JJ, May JF, Gans RO, Crijns HJ, Cohen Tervaert JW. Secondary prevention with fluvastatin decreases levels of adhesion molecules, neopterin and C-reactive protein. *Eur J Intern Med* 2001; **12**: 503–509.

60 Tardif J, McMurray JJ, Klug E et al. Aggressive Reduction of Inflammation Stops Events (ARISE) Trial Investigators. Effects of Succinobucol (AGI-1067) after an acute coronary syndrome: a randomized, double-blind, placebo-controlled trial. *Lancet* 2008; **371**: 1761–1768.

61 Wildman RP, Muntner P, Chen J, Sutton-Tyrrell K, He J. Relation of inflammation to peripheral arterial disease in the National Health and Nutrition Examination Survey, 1999–2002. *Am J Cardiol* 2005; **96**: 1579–1583.

62 Nasir K, Guallar E, Navas-Acien A, Criqui MH, Lima JA. Relationship of monocyte count and peripheral arterial disease. Results from the National Health and Nutrition Examination Survey 1999–2002. *Arterioscler Thromb Vasc Biol* 2005; **25**: 1966–1971.

63 Grau AJ, Boddy AW, Dukovic DA et al. Leukocyte count as an independent predictor of recurrent ischemic events. *Stroke* 2004; **35**: 1147–1152.

64 Haumer M, Amighi J, Exner M et al. Association of neutrophils and future cardiovascular events in patients with peripheral artery disease. *J Vasc Surg* 2005; **41**: 610–617.

65 Libby P. Inflammation in atherosclerosis. *Nature* 2002; **420**: 868–874.

66 Coller BS. Leukocytosis and ischemic vascular disease morbidity and mortality: is it time to intervene. *Arterioscler Thromb Vasc Biol* 2005; **25**: 658–670.

67 Madjid M, Awan I, Willerson JT, Casscells SW. Leukocyte count and coronary heart disease: implications for risk assessment. *J Am Coll Cardiol* 2004; **44**: 1945–1956.

68 Wilson AM, Kimura E, Harada RK et al. Beta2-microglobulin as a biomarker in peripheral arterial disease: proteomic profiling and clinical studies. *Circulation* 2007; **116**: 1396–1403.

69 Hoogeveen RC, Morrison A, Boerwinkle E et al. Plasma MCP-1 level and risk for peripheral arterial disease and incident coronary heart disease: Atherosclerosis Risk in Communities study. *Atherosclerosis* 2005; **183**: 301–307.

70 Lee WJ, Sheu WH, Chen YT et al. Circulating CD40 ligand is elevated only in patients with more advanced

symptomatic peripheral arterial diseases. *Thromb Res* 2005; **118**: 619–626.

71 Brevetti G, Schiano V, Laurenzano E et al. Myeloperoxidase, but not C-reactive protein, predicts cardiovascular risk in peripheral arterial disease. *Eur Heart J* 2008; **29**: 224–230.

72 Ali Z, Sarcia P, Mosley TH Jr., Kondragunta V, Kullo IJ. Association of serum myeloperoxidase with peripheral arterial disease. *Vasc Med* 2009 (in press).

73 Ali Z, Ellington AA, Mosley TH Jr., Kullo IJ. Association of serum osteoprotegerin with ankle-brachial index and urine albumin: creatinine ratio in African-Americans and non-Hispanic whites. *Atherosclerosis* 2009 Apr 5. [Epub ahead of print]

74 Barani J, Nilsson JA, Mattiasson I, Lindblad B, Gottsater A. Inflammatory mediators are associated with 1-year mortality in critical limb ischemia. *J Vasc Surg* 2005; **42**: 75–80.

75 Hamsten A, Iselius L, de Faire U, Blomback M. Genetic and cultural inheritance of plasma fibrinogen concentration. *Lancet* 1987; **ii**: 988–991.

76 Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. *Ann Intern Med* 1993; **118**: 956–963.

77 Ernst E, Matrai A. Abstention from chronic cigarette smoking normalizes blood rheology. *Atherosclerosis* 1987; **64**: 75–77.

78 Smith FB, Lee AJ, Hau CM, Rumley A, Lowe GD, Fowkes FG. Plasma fibrinogen, haemostatic factors and prediction of peripheral arterial disease in the Edinburgh Artery Study. *Blood Coagul Fibrinolysis* 2000; **11**: 43–50.

79 Wattanakit K, Folsom AR, Selvin E et al. Risk factors for peripheral arterial disease incidence in persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. *Atherosclerosis* 2005; **180**: 389–397.

80 Murabito JM, D'Agostino RB, Silbershatz H, Wilson PWF. Intermittent claudication: a risk profile from The Framingham Heart Study. *Circulation* 1997; **96**: 44–49.

81 Makin AJ, Chung NA, Silverman SH, Lip GY. Thrombogenesis and endothelial damage/dysfunction in peripheral artery disease. Relationship to ethnicity and disease severity. *Thromb Res* 2003; **111**: 221–226.

82 Lane JS, Vittinghoff E, Lane KT, Hiramoto JS, Messina LM. Risk factors for premature peripheral vascular disease: results for the National Health and Nutritional Survey, 1999–2002. *J Vasc Surg* 2006; **44**: 319–324.

83 Meijer WT, Grobbee DE, Hunink MG, Hofman A, Hoes AW. Determinants of peripheral arterial disease in the elderly: the Rotterdam study. *Arch Intern Med* 2000; **160**: 2934–2938.

84 Klein RL, Hunter SJ, Jenkins AJ et al. Fibrinogen is a marker for nephropathy and peripheral vascular disease in type 1 diabetes: studies of plasma fibrinogen and fibrinogen gene polymorphism in the DCCT/EDIC cohort. *Diabetes Care* 2003; **26**: 1439–1448.

85 Philipp CS, Cisar LA, Kim HC, Wilson AC, Saidi P, Kostis JB. Association of hemostatic factors with peripheral vascular disease. *Am Heart J* 1997; **134**: 978–984.

86 Khawaja F, Turner S, Kardia S, Mosle Jr T, Bailey K, Kullo IJ. Novel risk factors are associated with ankle brachial index in African Americans and non-Hispanic whites. *J Am Coll Cardiol* 2006; Suppl A: 294A.

87 Lowe GD, Fowkes FG, Dawes J, Donnan PT, Lennie SE, Housley E. Blood viscosity, fibrinogen, and activation of coagulation and leukocytes in peripheral arterial disease and the normal population in the Edinburgh Artery Study. *Circulation* 1993; **87**: 1915–1920.

88 Tzoulaki I, Murray GD, Price JF et al. Hemostatic factors, inflammatory markers, and progressive peripheral atherosclerosis: the Edinburgh Artery Study. *Am J Epidemiol* 2006; **163**: 334–341.

89 Doweik L, Maca T, Schillinger M, Budinsky A, Sabeti S, Minar E. Fibrinogen predicts mortality in high risk patients with peripheral artery disease. *Eur J Vasc Endovasc Surg* 2003; **26**: 381–386.

90 Folsom A. *Fibrinogen and cardiovascular risk in the Atherosclerosis Risk in Communities (ARIC) study.* In: Ernst E (ed). Fibrinogen, a 'new' cardiovascular risk factor. Oxford: Blackwell, 1992.

91 Manolio TA, Furberg CD, Shemanski L et al. Associations of postmenopausal estrogen use with cardiovascular disease and its risk factors in older women. The CHS Collaborative Research Group. *Circulation* 1993; **88**: 2163–2171.

92 Ernst E. Lowering the plasma fibrinogen concentration with drugs. *Clin Pharm* 1992; **11**: 968–971.

93 Meade T, Zuhrie R, Cook C, Cooper J. Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. *BMJ* 2002; **325**: 1139.

94 Lee AJ, Fowkes FG, Lowe GD, Rumley A. Fibrin D-dimer, haemostatic factors and peripheral arterial disease. *Thromb Haemost* 1995; **74**: 828–832.

95 Reich LM, Heiss G, Boland LL, Hirsch AT, Wu K, Folsom AR. Ankle-brachial index and hemostatic markers in the Atherosclerosis Risk in Communities (ARIC) study cohort. *Vasc Med* 2007; **12**: 267–273.

96 Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD, Fowkes FG. Inflammatory, haemostatic, and rheological markers for incident peripheral arterial disease: Edinburgh Artery Study. *Eur Heart J* 2007; **28**: 354–362.

97 Packard CJ, O'Reilly DS, Caslake MJ et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. *N Engl J Med* 2000; **343**: 1148–1155.

98 Kardys I, Oei HH, van der Meer IM, Hofman A, Breteler MM, Witteman JC. Lipoprotein-associated phospholipase A2 and measures of extracoronary atherosclerosis: the Rotterdam Study. *Arterioscler Thromb Vasc Biol* 2006; **26**: 631–636.

99 Allison MA, Denenberg JO, Nelson JJ, Natarajan L, Criqui MH. The association between lipoprotein-associated phospholipase A2 and cardiovascular disease and total mortality in vascular medicine patients. *J Vasc Surg* 2007; **46**: 500–506.

100 Loscalzo J. Lipoprotein(a). A unique risk factor for atherothrombotic disease. *Arteriosclerosis* 1990; **10**: 672–679.

101 Li XN, Grenett HE, Benza RL et al. Genotype-specific transcriptional regulation of PAI-1 expression by hypertriglyceridemic VLDL and Lp(a) in cultured human endothelial cells. *Arterioscler Thromb Vasc Biol* 1997; **17**: 3215–3223.

102 Levin EG, Miles LA, Fless GM et al. Lipoproteins inhibit the secretion of tissue plasminogen activator from human endothelial cells. *Arterioscler Thromb* 1994; **14**: 438–442.

103 Grainger DJ, Kirschenlohr HL, Metcalfe JC, Weissberg PL, Wade DP, Lawn RM. Proliferation of human smooth muscle cells promoted by lipoprotein(a). *Science* 1993; **260**: 1655–1658.

104 Valentine RJ, Grayburn PA, Vega GL, Grundy SM. Lp (a) lipoprotein is an independent, discriminating risk factor for premature peripheral atherosclerosis among white men. *Arch Intern Med* 1994; **154**: 801–806.

105 Valentine RJ, Kaplan HS, Green R, Jacobsen DW, Myers SI, Clagett GP. Lipoprotein (a), homocysteine, and hypercoagulable states in young men with premature peripheral atherosclerosis: a prospective, controlled analysis. *J Vasc Surg* 1996; **23**: 53–61.

106 Widmann MD, Sumpio BE. Lipoprotein (a): a risk factor for peripheral vascular disease. *Ann Vasc Surg* 1993; **7**: 446–451.

107 Cheng SW, Ting AC, Wong J. Lipoprotein (a) and its relationship to risk factors and severity of atherosclerotic peripheral vascular disease. *Eur J Vasc Endovasc Surg* 1997; **14**: 17–23.

108 Sofi F, Lari B, Rogolino A et al. Thrombophilic risk factors for symptomatic peripheral arterial disease. *J Vasc Surg* 2005; **41**: 255–260.

109 Sutton-Tyrrell K, Evans RW, Meilahn E, Alcorn HG. Lipoprotein(a) and peripheral atherosclerosis in older adults. *Atherosclerosis* 1996; **122**: 11–19.

110 Tseng CH. Lipoprotein(a) is an independent risk factor for peripheral arterial disease in Chinese type 2 diabetic patients in Taiwan. *Diabetes Care* 2004; **27**: 517–521.

111 Kraft HG, Lingenhel A, Kochl S et al. Apolipoprotein(a) kringle IV repeat number predicts risk for coronary heart disease. *Arterioscler Thromb Vasc Biol* 1996; **16**: 713–719.

112 Kronenberg F, Kronenberg MF, Kiechl S et al. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study. *Circulation* 1999; **100**: 1154–1160.

113 Marcovina SM, Albers JJ, Wijsman E, Zhang Z, Chapman NH, Kennedy H. Differences in Lp(a) concentrations and apo(a) polymorphs between black and white Americans. *J Lipid Res* 1996; **37**: 2569–2585.

114 Moliterno DJ, Jokinen EV, Miserez AR et al. No association between plasma lipoprotein(a) concentrations and the presence or absence of coronary atherosclerosis in African-Americans. *Arterioscler Thromb Vasc Biol* 1995; **15**: 850–855.

115 Paultre F, Pearson TA, Weil HF et al. High levels of Lp(a) with a small apo(a) isoform are associated with coronary artery disease in African American and white men. *Arterioscler Thromb Vasc Biol* 2000; **20**: 2619–2624.

116 Kostner GM, Gavish D, Leopold B, Bolzano K, Weintraub MS, Breslow JL. HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. *Circulation* 1989; **80**: 1313–1319.

117 Maher VM, Brown BG, Marcovina SM, Hillger LA, Zhao XQ, Albers JJ. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). *JAMA* 1995; **274**: 1771–1774.

118 Sacks FM, McPherson R, Walsh BW. Effect of postmenopausal estrogen replacement on plasma Lp(a) lipoprotein concentrations. *Arch Intern Med* 1994; **154**: 1106–1110.

119 Shlipak MG, Simon JA, Vittinghoff E et al. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. *JAMA* 2000; **283**: 1845–1852.

120 Morgan JM, Capuzzi DM, Guyton JR. A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. *Am J Cardiol* 1998; **12A**: 29U–34U.

121 Gurakar A, Hoeg JM, Kostner G, Papadopoulos NM, Brewer Jr HB. Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment. *Atherosclerosis* 1985; **57**: 293–301.

122 Kashyap ML, McGovern ME, Berra K et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. *Am J Cardiol* 2002; **89**: 672–678.

123 Welch GN, Loscalzo J. Homocysteine and atherothrombosis. *N Engl J Med* 1998; **338**: 1042–1050.

124 Jacques PF, Bostom AG, Williams RR et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. *Circulation* 1996; **93**: 7–9.

125 Kang SS, Wong PW, Cook HY, Norusis M, Messer JV. Protein-bound homocyst(e)ine. A possible risk factor for coronary artery disease. *J Clin Invest* 1986; **77**: 1482–1486.

126 Nedrebo BG, Ericsson UB, Nygard O et al. Plasma total homocysteine levels in hyperthyroid and hypothyroid patients. *Metabolism* 1998; **47**: 89–93.

127 Ubbink JB, Vermaak WJ, van der Merwe A, Becker PJ. Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia. *Am J Clin Nutr* 1993; **57**: 47–53.

128 Bostom AG, Culleton BF. Hyperhomocysteinemia in chronic renal disease. *J Am Soc Nephrol* 1999; **10**: 891–900.

129 Darius H, Pittrow D, Haberl R et al. Are elevated homocysteine plasma levels related to peripheral arterial disease? Results from a cross-sectional study of 6880 primary care patients. *Eur J Clin Invest* 2003; **33**: 751–757.

130 Ciccarone E, Di Castelnuovo A, Assanelli D et al. Homocysteine levels are associated with the severity of peripheral arterial disease in Type 2 diabetic patients. *J Thromb Haemost* 2003; **1**: 2540–2547.

131 Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. *JAMA* 1995; **274**: 1049–1057.

132 Taylor Jr LM, Moneta GL, Sexton GJ, Schuff RA, Porter JM. Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease. *J Vasc Surg* 1999; **29**: 8–19.

133 Lange S, Trampisch HJ, Haberl R et al. Excess 1-year cardiovascular risk in elderly primary care patients with a low ankle-brachial index (ABI) and high homocysteine level. *Atherosclerosis* 2005; **178**: 351–357.

134 Guallar E, Silbergeld EK, Navas-Acien A et al. Confounding of the relation between homocysteine and peripheral arterial disease by lead, cadmium, and renal function. *Am J Epidemiol* 2006; **163**: 700–708.

135 Lonn E, Yusuf S, Arnold MJ et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. *N Engl J Med* 2006; **354**: 1567–1577.

136 Albert CM, Cook NR, Gaziano JM et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for

cardiovascular disease: a randomized trial. *JAMA* 2008; **299**: 2027–2036.

137 Boger RH, Bode-Boger SM, Thiele W, Junker W, Alexander K, Frolich JC. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. *Circulation* 1997; **95**: 2068–2074.

138 Mittermayer F, Krzyzanowska K, Exner M et al. Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced peripheral artery disease. *Arterioscler Thromb Vasc Biol* 2006; **26**: 2536–2540.

139 Boger RH, Bode-Boger SM, Thiele W, Creutzig A, Alexander K, Frolich JC. Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. *J Am Coll Cardiol* 1998; **32**: 1336–1344.

140 Wilson AM, Harada R, Nair N, Balasubramanian N, Cooke JP. L-Arginine supplementation in peripheral arterial disease: no benefit and possible harm. *Circulation* 2007; **116**: 188–195.

141 Madamanchi NR, Vendrov A, Runge MS. Oxidative stress and vascular disease. *Arterioscler Thromb Vasc Biol* 2005; **25**: 29–38.

142 Pipinos II, Judge AR, Zhu Z et al. Mitochondrial defects and oxidative damage in patients with peripheral arterial disease. *Free Radic Biol Med* 2006; **41**: 262–269.

143 Makin AJ, Chung NA, Silverman SH, Lip GY. Vascular endothelial growth factor and tissue factor in patients with established peripheral artery disease: a link between angiogenesis and thrombogenesis. *Clin Sci (Lond)* 2003; **104**: 397–404.

144 Tayebjee MH, Tan KT, MacFadyen RJ, Lip GY. Abnormal circulating levels of metalloprotease 9 and its tissue inhibitor 1 in angiographically proven peripheral arterial disease: relationship to disease severity. *J Intern Med* 2005; **257**: 110–116.

145 Signorelli SS, Malaponte G, Libra M et al. Plasma levels and zymographic activities of matrix metalloproteinases 2 and 9 in type II diabetics with peripheral arterial disease. *Vasc Med* 2005; **10**: 1–6.

146 Mueller T, Dieplinger B, Poelz W, Haltmayer M. Increased pregnancy-associated plasma protein-A as a marker for peripheral atherosclerosis: results from the Linz Peripheral Arterial Disease Study. *Clin Chem* 2006; **52**: 1096–1103.

147 Blann AD, Belgore FM, McCollum CN, Silverman S, Lip PL, Lip GY. Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or Type II diabetes. *Clin Sci (Lond)* 2002; **102**: 187–194.

148 Findley CM, Mitchell RG, Duscha BD, Annex BH, Kontos CD. Plasma levels of soluble Tie2 and vascular endothelial growth factor distinguish critical limb ischemia from intermittent claudication in patients with peripheral arterial disease. *J Am Coll Cardiol* 2008; **52**: 387–393.

149 Allison MA, Criqui MH, McClelland RL et al. The effect of novel cardiovascular risk factors on the ethnic-specific odds for peripheral arterial disease in the Multi-Ethnic Study of Atherosclerosis (MESA). *J Am Coll Cardiol* 2006; **48**: 1190–1197.